Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc. (NASDAQ: MRNA) said that following positive feedback from the U.S. Food and Drug Administration, it is pursuing a plan to increase the number of COVID-19 vaccine doses to up to 15 in each vial from the present 10 doses. What Happened: The plan was disclosed as part of the biotechnology company's written testimony ahead of a House hearing scheduled for Tuesday.

Moderna Prepares To Increase Doses In Each COVID-19 Vaccine Vial To Counter Production Woes

Moderna said it received "positive feedback" from the FDA on its proposal to increase the number of Covid-19 vaccine doses in each of its vials.

Moderna says FDA gave positive feedback on request to increase Covid vaccine supply in each vial

Investors are likely to focus on Moderna's (MRNA) sales guidance for its coronavirus vaccine in 2021 on the fourth-quarter earrings call.

Coronavirus Vaccine Sales Key to Moderna's (MRNA) Q4 Earnings

The biotech's messenger RNA platform is promising. But some investors could have qualms about its current valuation.

What Are the Long-Term Prospects for Moderna?

Airbnb

DoorDash

DraftKings

Home Depot

NVIDIA

Best Buy

Salesforce

Medtronic

Nikola

Palo Alto Networks

Block

Here, 24/7 Wall St. has put together a preview of a few of the most anticipated quarterly reports due this week.

Airbnb, DoorDash, DraftKings, Home Depot, Nvidia and More Major Earnings Coming This Week

Novavax

There's plenty to like about both of these high-flying biotech stocks.

Better Coronavirus Stock: Moderna or Novavax?

These elements will set the stage for the rest of the year.

Here's What I'll Be Looking for in Moderna's Earnings Report Next Week

The stock price of Moderna Inc (NASDAQ: MRNA) has received a price target increase from $150 to $215 by Morgan Stanley. These are the details.

MRNA Stock Price: $215 Target (Up From $150) By Morgan Stanley

ADMA Biologics

Atea Pharmaceuticals

BioNTech SE

Lexicon Pharmaceuticals

Let us take a look at some drug/biotech stocks that are poised to beat on fourth-quarter earnings.

4 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Investor focus is likely to be on any update on the timeline of filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the fourth-quarter earrings call.

Is a Beat in Store for Moderna (MRNA) This Earnings Season?

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to present at upcoming investor conferences in February and March 2021.

Moderna to Present at Upcoming Investor Conferences in February and March 2021

Pfizer

Insiders at Pfizer Inc. (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA) and other COVID-19 vaccine makers collectively sold nearly half a billion dollars worth of their stock but one pro isn't alarmed by the trend, The Wall Street Journal reported. What are insider trades?

What to make of Pfizer, Moderna insiders dumping stock?

Shares of Moderna Inc. were down 0.9% in premarket trading on Wednesday after the company said the European Commission bought an additional 150 million doses of its COVID-19 vaccine. This round of vaccine is expected to be delivered in the second half of 2021 and brings Europe's total order to 310 million doses of Moderna's two-dose mRNA-based vaccine.

Europe orders an additional 150 million doses of Moderna's vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--European Commission purchases additional 150 million doses of COVID-19 Vaccine Moderna.

European Commission Purchases Additional 150 Million Doses of COVID-19 Vaccine Moderna

MRNA's valuation rose 15% after a positive data read-out of NVAX's COVID-19 vaccine. MRNA's rise seemed inexplicable. The emergence of vaccines from NVAX and JNJ could potentially threaten MRNA and PFE.

Moderna's Valuation Is Untenable

Manufacturing capacity is increasing dramatically despite the short-term issue.

Moderna Hits a Short-Term Vaccine Manufacturing Delay, Still on Track for First 100 Million Doses by End of March

Moderna Inc. provided on Tuesday an update of the supply of its COVID-19 vaccine, saying it expects to deliver 100 million doses to the U.S. Government by the end of March. The company said it moved up the expected delivery of its second 100 million doses to the end of May from the end of June, and its third 100 million doses to the end of July, from the end of September.

Moderna moves up expected delivery of 300 million COVID-19 vaccine doses to end of July

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna provides U.S. COVID-19 Vaccine supply update.

Moderna Provides U.S. COVID-19 Vaccine Supply Update

Tilray Brands

Zynga

Here's how a boutique online game developer, a coronavirus vaccine developer, and the largest cannabis company in the world can all add wealth to your portfolio.

3 Extraordinary Growth Stocks to Buy Now

Should You Be Concerned About COVID Vaccine Efficacy Against the South African Variant?

Johnson & Johnson

It's simply not an apples-to-apples comparison.

Here's Why You Can't Compare Vaccine Results Between Johnson & Johnson, Pfizer, and Moderna

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Canada purchases additional 4 million doses of Moderna's COVID-19 Vaccine

Canada Purchases Additional 4 Million Doses of Moderna's COVID-19 Vaccine

CureVac B.V

Coronavirus vaccine news supply deals and a regulatory filing are in the headlines in Friday's trading session.  US Secures More Vaccine Doses: Moderna Inc (NASDAQ: MRNA) and Pfizer Inc. (NYSE: PFE), the two companies that have received  emergency use authorization for vaccine candidates in the U.S., confirmed supply deals with the federal government.

COVID-19 Vaccine Updates: US Strikes 100M-Dose Supply Deals With Moderna, Pfizer, EU Starts Rolling Review Of CureVac Vaccine

How Long Until We Reach Herd Immunity? Expert Timelines Vary

Moderna Inc. said late Thursday the U.S. government has bought an additional 100 million doses of the company's COVID-19 vaccine, bringing its confirmed order commitment to 300 million doses. Moderna already has supplied 41 million doses to date, and more than 22 million U.S. residents have received the vaccine, the second to be approved in the U.S. Moderna remains on track to deliver the first 100 million doses in the first quarter of 2021 and the second order of 100 million doses would be delivered in the second quarter of 2021.

News for Moderna Stock (MRNA)